ResMed/$RMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ResMed
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
Ticker
$RMD
Sector
Primary listing
NYSE
Employees
10,600
Headquarters
Website
ResMed Metrics
BasicAdvanced
$27bn
18.19
$10.37
0.78
$2.40
1.27%
Price and volume
Market cap
$27bn
Beta
0.78
52-week high
$293.81
52-week low
$180.27
Average daily volume
1.5m
Dividend rate
$2.40
Financial strength
Current ratio
3.008
Quick ratio
2.003
Long term debt to equity
8.534
Total debt to equity
12.988
Dividend payout ratio (TTM)
22.39%
Profitability
EBITDA (TTM)
2,119.501
Gross margin (TTM)
62.18%
Net profit margin (TTM)
27.44%
Operating margin (TTM)
34.71%
Effective tax rate (TTM)
20.16%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
14.69%
Return on equity (TTM)
25.25%
Valuation
Price to earnings (TTM)
18.189
Price to revenue (TTM)
4.972
Price to book
4.22
Price to tangible book (TTM)
9.07
Price to free cash flow (TTM)
15.858
Free cash flow yield (TTM)
6.31%
Free cash flow per share (TTM)
11.895
Dividend yield (TTM)
1.27%
Forward dividend yield
1.27%
Growth
Revenue change (TTM)
10.28%
Earnings per share change (TTM)
16.39%
3-year revenue growth (CAGR)
11.31%
10-year revenue growth (CAGR)
12.06%
3-year earnings per share growth (CAGR)
20.96%
10-year earnings per share growth (CAGR)
15.24%
3-year dividend per share growth (CAGR)
10.22%
10-year dividend per share growth (CAGR)
7.04%
What the Analysts think about ResMed
Analyst ratings (Buy, Hold, Sell) for ResMed stock.
ResMed Financial Performance
Revenues and expenses
ResMed Earnings Performance
Company profitability
ResMed News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs